Stratifying Risk in Oligoprogressive EGFR-Mutated Non-Small Cell Lung Cancer: The Role of ctDNA

被引：0
|
作者：
Arrieta, O. [1 ]
Guijosa, A. [1 ]
Heredia, D. [1 ]
Davila-Dupont, D. [1 ]
Rios-Garcia, E. [1 ]
机构：
[1] Natl Canc Inst Mexico INCan, Mexico City, DF, Mexico
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.06D.05
引用
收藏
页码：S323 / S324
页数：2
相关论文
共 50 条
  • [31] Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Sequist, L. V.
    Soria, J-C
    Goldman, J. W.
    Wakelee, H. A.
    Gadgeel, S. M.
    Varga, A.
    Papadimitrakopoulou, V.
    Solomon, B. J.
    Oxnard, G. R.
    Dziadziuszko, R.
    Aisner, D. L.
    Doebele, R. C.
    Galasso, C.
    Garon, E. B.
    Heist, R. S.
    Logan, J.
    Neal, J. W.
    Mendenhall, M. A.
    Nichols, S.
    Piotrowska, Z.
    Wozniak, A. J.
    Raponi, M.
    Karlovich, C. A.
    Jaw-Tsai, S.
    Isaacson, J.
    Despain, D.
    Matheny, S. L.
    Rolfe, L.
    Allen, A. R.
    Camidge, D. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18): : 1700 - 1709
  • [32] Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
    Ouyang, Wen
    Yu, Jing
    Zhou, Yan
    Hu, Jing
    Huang, Zhao
    Zhang, Junhong
    Xie, Conghua
    BMC CANCER, 2020, 20 (01)
  • [33] EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?
    Liu, Bailong
    Liu, Hui
    Ma, Yunfei
    Ding, Qiuhui
    Zhang, Min
    Liu, Xinliang
    Liu, Min
    CANCER MEDICINE, 2021, 10 (18): : 6167 - 6188
  • [34] Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
    Eltayeb, Kamal
    La Monica, Silvia
    Tiseo, Marcello
    Alfieri, Roberta
    Fumarola, Claudia
    CELLS, 2022, 11 (03)
  • [35] MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer
    Yan, D.
    Huelse, J.
    Parker, R.
    Wang, X.
    Frye, S.
    Earp, H. S.
    Deryckere, D.
    Graham, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1147 - S1147
  • [36] Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
    Leonetti, Alessandro
    Facchinetti, Francesco
    Tiseo, Marcello
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [37] Tumor PKCδ instigates immune exclusion in EGFR-mutated non-small cell lung cancer
    Zuo, Yi-Han
    Gao, Wei-Na
    Xie, Ya-Jia
    Yang, Sheng-Yong
    Zhou, Jin-Tai
    Liang, Hai-Hai
    Fan, Xing-Xing
    BMC MEDICINE, 2022, 20 (01)
  • [38] Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism
    Hotta, Takamasa
    Tsubata, Yukari
    Hamai, Kosuke
    Tanino, Akari
    Kobayashi, Misato
    Nakamura, Atsushi
    Sugisaka, Jun
    Hongoh, Masafumi
    Ishihara, Noriyuki
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Fujitaka, Kazunori
    Kubota, Tetsuya
    Nishimura, Nobuhiro
    Isobe, Takeshi
    RESPIRATORY INVESTIGATION, 2021, 59 (03) : 327 - 334
  • [39] RNA Sequencing to Characterize Pathways in Patients with EGFR-mutated Non-Small Cell Lung Cancer
    Yun, N. K.
    Pope, C.
    Cagin, K. M.
    Naqib, A.
    Borgia, J. A.
    Fidler, M. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S449 - S449
  • [40] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Fu, Kai
    Xie, Fachao
    Wang, Fang
    Fu, Liwu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
12345